Xencor, Inc. (NASDAQ:XNCR – Get Free Report) has received a consensus rating of “Moderate Buy” from the eleven brokerages that are currently covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, three have issued a hold recommendation, six have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month price target among brokerages that have issued a report on the stock in the last year is $34.00.
XNCR has been the subject of a number of research reports. Bank of America increased their price target on Xencor from $20.00 to $26.00 and gave the company a “neutral” rating in a research note on Monday, September 21st. Barclays raised their price target on Xencor from $27.00 to $35.00 and gave the company an “overweight” rating in a report on Friday, September 11th. Cantor Fitzgerald lifted their price objective on Xencor from $43.00 to $44.00 and gave the stock an “overweight” rating in a research note on Thursday, August 6th. Wedbush reaffirmed an “outperform” rating and set a $30.00 price objective on shares of Xencor in a report on Wednesday. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Xencor in a research report on Monday, September 21st.
Xencor Price Performance
Shares of XNCR opened at $25.18 on Wednesday. The firm has a market cap of $1.87 billion, a P/E ratio of -11.60 and a beta of 0.89. Xencor has a 1 year low of $10.38 and a 1 year high of $30.61. The company has a 50 day simple moving average of $25.37 and a two-hundred day simple moving average of $18.38.
Xencor (NASDAQ:XNCR – Get Free Report) last released its earnings results on Wednesday, August 5th. The biopharmaceutical company reported ($0.29) EPS for the quarter, topping the consensus estimate of ($0.80) by $0.51. The firm had revenue of $51.22 million for the quarter, compared to the consensus estimate of $18.89 million. Xencor had a negative net margin of 155.59% and a negative return on equity of 28.66%. The company’s quarterly revenue was up 17.4% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.41) earnings per share. On average, sell-side analysts anticipate that Xencor will post -3.05 earnings per share for the current year.
Hedge Funds Weigh In On Xencor
Several institutional investors have recently bought and sold shares of XNCR. GAMMA Investing LLC lifted its holdings in shares of Xencor by 15.5% in the 3rd quarter. GAMMA Investing LLC now owns 4,269 shares of the biopharmaceutical company’s stock valued at $107,000 after acquiring an additional 572 shares during the last quarter. WINTON GROUP Ltd raised its position in Xencor by 1.5% during the second quarter. WINTON GROUP Ltd now owns 106,247 shares of the biopharmaceutical company’s stock valued at $1,711,000 after purchasing an additional 1,534 shares during the period. Integrated Wealth Concepts LLC purchased a new stake in Xencor during the second quarter valued at approximately $30,000. Squarepoint Ops LLC bought a new stake in shares of Xencor in the 2nd quarter valued at approximately $459,000. Finally, Allworth Financial LP lifted its stake in shares of Xencor by 23.2% in the 2nd quarter. Allworth Financial LP now owns 3,436 shares of the biopharmaceutical company’s stock valued at $55,000 after purchasing an additional 646 shares during the last quarter.
About Xencor
Xencor, Inc is a clinical-stage biopharmaceutical company headquartered in Monrovia, California. Founded in 1997, the company develops engineered antibodies and other biologic medicines for the treatment of cancer, autoimmune disorders and other serious diseases.
Xencor’s research is centered on its XmAb technology platform, which is designed to modify antibodies to improve their therapeutic properties or create new antibody-based mechanisms. The platform supports the development of bispecific antibodies, immune-cell engagers and antibodies with extended activity in the body.
Featured Stories
- Five stocks we like better than Xencor
- Spotify Soars After Earnings as the Company Touts AI Benefits and Moderating Costs
- Lockheed Martin’s Record $292 Billion Backlog Comes With a Delivery Test
- Palantir’s Next Big Test Isn’t a Partnership—It’s the Numbers
- Kinder Morgan’s $4.7 Billion Pipeline Bet Could Be Bigger Than Its Earnings Beat
Receive News & Ratings for Xencor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor and related companies with MarketBeat.com's FREE daily email newsletter.
